vs
CareCloud, Inc.（CCLD）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是CareCloud, Inc.的1.0倍（$35.5M vs $34.4M），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 21.9%），CareCloud, Inc.自由现金流更多（$6.6M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 15.1%）
CareCloud, Inc.是一家上市的美国医疗信息技术企业，主要为各类医疗机构、医院提供专业医疗信息化相关服务，公司总部位于新泽西州萨默塞特，目前在全球拥有约四千名员工。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CCLD vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.0倍
$34.4M
营收增速更快
RXRX
高出659.8%
21.9%
自由现金流更多
CCLD
多$53.9M
$-47.3M
两年增速更快
RXRX
近两年复合增速
15.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.4M | $35.5M |
| 净利润 | — | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 9.1% | -304.8% |
| 净利率 | — | -304.2% |
| 营收同比 | 21.9% | 681.7% |
| 净利润同比 | — | 39.6% |
| 每股收益（稀释后） | $0.06 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCLDRXRX
| Q4 25 | $34.4M | $35.5M | ||
| Q3 25 | $31.1M | $5.2M | ||
| Q2 25 | $27.4M | $19.2M | ||
| Q1 25 | $27.6M | $14.7M | ||
| Q4 24 | $28.2M | $4.5M | ||
| Q3 24 | $28.5M | $26.1M | ||
| Q2 24 | $28.1M | $14.4M | ||
| Q1 24 | $26.0M | $13.8M |
净利润CCLDRXRX
| Q4 25 | — | $-108.1M | ||
| Q3 25 | $3.1M | $-162.3M | ||
| Q2 25 | $2.9M | $-171.9M | ||
| Q1 25 | $1.9M | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | $3.1M | $-95.8M | ||
| Q2 24 | $1.7M | $-97.5M | ||
| Q1 24 | $-241.0K | $-91.4M |
毛利率CCLDRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率CCLDRXRX
| Q4 25 | 9.1% | -304.8% | ||
| Q3 25 | 10.3% | -3327.6% | ||
| Q2 25 | 10.9% | -916.8% | ||
| Q1 25 | 7.3% | -1297.9% | ||
| Q4 24 | 12.2% | -4042.4% | ||
| Q3 24 | 11.4% | -377.1% | ||
| Q2 24 | 8.1% | -697.4% | ||
| Q1 24 | 0.5% | -698.4% |
净利率CCLDRXRX
| Q4 25 | — | -304.2% | ||
| Q3 25 | 9.8% | -3135.3% | ||
| Q2 25 | 10.6% | -894.2% | ||
| Q1 25 | 7.0% | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | 10.9% | -367.5% | ||
| Q2 24 | 6.0% | -676.6% | ||
| Q1 24 | -0.9% | -662.4% |
每股收益（稀释后）CCLDRXRX
| Q4 25 | $0.06 | $-0.17 | ||
| Q3 25 | $0.04 | $-0.36 | ||
| Q2 25 | $0.04 | $-0.41 | ||
| Q1 25 | $-0.04 | $-0.50 | ||
| Q4 24 | $0.00 | $-0.56 | ||
| Q3 24 | $-0.04 | $-0.34 | ||
| Q2 24 | $-0.14 | $-0.40 | ||
| Q1 24 | $-0.10 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | $1.2M | $9.6M |
| 股东权益账面价值 | $59.5M | $1.1B |
| 总资产 | $87.6M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.02× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资CCLDRXRX
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务CCLDRXRX
| Q4 25 | $1.2M | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | $336.0K | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益CCLDRXRX
| Q4 25 | $59.5M | $1.1B | ||
| Q3 25 | $57.8M | $1.0B | ||
| Q2 25 | $56.1M | $919.1M | ||
| Q1 25 | $54.2M | $933.9M | ||
| Q4 24 | $49.8M | $1.0B | ||
| Q3 24 | $46.5M | $524.6M | ||
| Q2 24 | $43.2M | $584.4M | ||
| Q1 24 | $41.4M | $401.2M |
总资产CCLDRXRX
| Q4 25 | $87.6M | $1.5B | ||
| Q3 25 | $90.6M | $1.4B | ||
| Q2 25 | $75.2M | $1.3B | ||
| Q1 25 | $73.6M | $1.3B | ||
| Q4 24 | $71.6M | $1.4B | ||
| Q3 24 | $70.7M | $726.5M | ||
| Q2 24 | $74.0M | $775.9M | ||
| Q1 24 | $76.9M | $557.8M |
负债/权益比CCLDRXRX
| Q4 25 | 0.02× | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | 0.01× | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.7M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $6.6M | $-47.3M |
| 自由现金流率自由现金流/营收 | 19.0% | -133.1% |
| 资本支出强度资本支出/营收 | 6.2% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $23.8M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流CCLDRXRX
| Q4 25 | $8.7M | $-46.1M | ||
| Q3 25 | $7.4M | $-117.4M | ||
| Q2 25 | $7.4M | $-76.4M | ||
| Q1 25 | $5.1M | $-132.0M | ||
| Q4 24 | $5.2M | $-115.4M | ||
| Q3 24 | $7.1M | $-59.2M | ||
| Q2 24 | $4.3M | $-82.2M | ||
| Q1 24 | $4.1M | $-102.3M |
自由现金流CCLDRXRX
| Q4 25 | $6.6M | $-47.3M | ||
| Q3 25 | $6.5M | $-117.6M | ||
| Q2 25 | $6.2M | $-79.6M | ||
| Q1 25 | $4.5M | $-133.8M | ||
| Q4 24 | $4.3M | $-116.7M | ||
| Q3 24 | $6.7M | $-63.8M | ||
| Q2 24 | $4.2M | $-83.4M | ||
| Q1 24 | $3.8M | $-109.0M |
自由现金流率CCLDRXRX
| Q4 25 | 19.0% | -133.1% | ||
| Q3 25 | 20.9% | -2272.5% | ||
| Q2 25 | 22.8% | -413.9% | ||
| Q1 25 | 16.2% | -907.4% | ||
| Q4 24 | 15.2% | -2567.7% | ||
| Q3 24 | 23.6% | -244.6% | ||
| Q2 24 | 14.8% | -578.5% | ||
| Q1 24 | 14.5% | -789.9% |
资本支出强度CCLDRXRX
| Q4 25 | 6.2% | 3.5% | ||
| Q3 25 | 2.8% | 4.7% | ||
| Q2 25 | 4.2% | 16.4% | ||
| Q1 25 | 2.3% | 12.4% | ||
| Q4 24 | 3.3% | 28.6% | ||
| Q3 24 | 1.2% | 17.5% | ||
| Q2 24 | 0.5% | 8.2% | ||
| Q1 24 | 1.1% | 48.2% |
现金转化率CCLDRXRX
| Q4 25 | — | — | ||
| Q3 25 | 2.41× | — | ||
| Q2 25 | 2.55× | — | ||
| Q1 25 | 2.62× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.26× | — | ||
| Q2 24 | 2.56× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCLD
| Healthcare IT | $31.0M | 90% |
| Medical Practice Management | $3.4M | 10% |
RXRX
暂无分部数据
